Partial
Needs Correction
Patient Risk:
Moderate
Summary
Many mechanistic, resistance, antimicrobial activity, and several adverse effect statements align with the provided FDA label text. However, the response includes at least one clearly unsupported claim (IV formulation availability) and several other claims are unverifiable/unsupported because the provided label excerpts do not contain the needed information (e.g., FDA approval date, patent/generic availability, IV route, explicit clinician assessment instruction, and “weakened immune systems” phrasing).
Category Scores
Accurate Statements
Bactrim is a combination of trimethoprim and sulfamethoxazole.
CLINICAL PHARMACOLOGY: Mechanism of Action; DOSAGE AND ADMINISTRATION (uses both components).
The combination inhibits bacterial folic acid synthesis by blocking consecutive steps (sulfamethoxazole inhibits dihydrofolic acid synthesis; trimethoprim blocks conversion to tetrahydrofolic acid).
CLINICAL PHARMACOLOGY: Microbiology—Mechanism of Action.
Resistance develops more slowly with both drugs in combination than with either component alone.
CLINICAL PHARMACOLOGY: Microbiology—Resistance.
BACTRIM has antimicrobial activity against most isolates of multiple listed microorganisms, and includes Pneumocystis jirovecii.
CLINICAL PHARMACOLOGY: Microbiology—Antimicrobial Activity (and list includes Pneumocystis jirovecii).
Common adverse reactions include gastrointestinal disturbances such as nausea and vomiting; rash/urticaria are also among most common adverse reactions.
ADVERSE REACTIONS: “most common adverse reactions are gastrointestinal disturbances (nausea, vomiting, anorexia) and allergic skin reactions (such as rash and urticaria).”
More serious adverse reactions can include severe cutaneous reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS, AFND, AGEP), hepatic necrosis, and blood dyscrasias (e.g., agranulocytosis/aplastic anemia).
WARNINGS/ADVERSE REACTIONS: severe cutaneous adverse reactions; fulminant hepatic necrosis; agranulocytosis/aplastic anemia and other blood dyscrasias.
Bactrim is prescribed for urinary tract infections.
DOSAGE AND ADMINISTRATION: “Urinary Tract Infections… The usual adult dosage in the treatment of urinary tract infections…”
Bactrim is available in oral tablet formulations (tablets/BACTRIM DS tablets).
DOSAGE AND ADMINISTRATION references “BACTRIM DS (double strength) tablet” and “BACTRIM tablets.”
Unsupported Statements
Bactrim is available in intravenous (IV) formulations.
The provided label excerpts only reference oral administration and tablets; no IV formulation is mentioned.
Bactrim (trimethoprim/sulfamethoxazole) produces a synergistic effect.
No explicit “synergy” language is present in the provided label excerpts.
Bactrim (trimethoprim/sulfamethoxazole) is more potent than either drug alone.
The label states resistance develops more slowly with the combination, but does not explicitly claim “more potent than either drug alone.”
Bactrim was first approved by the U.S. FDA in 1973.
No FDA approval date/history is present in the provided label excerpts.
Bactrim was available since 1973.
No availability history/date is present in the provided label excerpts.
The original patents for Bactrim have long expired.
No patent information is present in the provided label excerpts.
Generic versions of trimethoprim/sulfamethoxazole are widely available.
No generic availability information is present in the provided label excerpts.
Healthcare providers should assess a patient's medical history before prescribing Bactrim.
No explicit instruction with this wording is present in the provided label excerpts.
Contradictions
Low
AI Statement
Bactrim is available in intravenous (IV) formulations.
Label Reference
Provided label excerpts do not mention IV formulation; administration-route claim is not supported.
Important Omissions
The response does not distinguish label-specific indications (e.g., Pneumocystis jirovecii pneumonia prophylaxis/treatment) with the exact labeled framing for patient populations; it also omits core safety contraindication details and key administration/dosing information.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
An unsupported administration-route claim (IV availability) could mislead route selection. Several other claims are unverified due to missing label excerpts (approval/patents/generic availability, clinician assessment wording). Most safety effect statements (nausea/vomiting/rash; severe cutaneous reactions, hepatic necrosis, blood dyscrasias) align with the provided text.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Needs Correction
Primary Issue
At least one claim is not supported by the provided FDA label excerpts (IV formulation availability), and several other claims are unverified/absent due to missing label information (approval date, patents/generic availability, explicit “synergy”/“more potent” statements, and clinician assessment wording).
Suggested Improvement
Remove or qualify unsupported items (especially IV formulation). Replace synergy/more-potent language with what the label actually states (mechanism and slower resistance development with combination). Avoid adding FDA approval dates, patent status, and generic availability unless explicitly supported by label excerpts.